LSD Trial Study Shows Potential For Major Depression

Psychedelics biopharma company Mind Medicine Inc. (NASDAQ:MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a treatment of Major Depressive Disorder (MDD). The double-blind Phase 2 study demonstrated "significant, rapid, durable and beneficial effects" on the mitigation of MDD symptoms. Read more HERE.

Canada's Large Scale Psilocybin Macrodose Trial

Canadian biopharma company Apex Labs Ltd., has received Health Canada's approval for a comprehensive, "statistically powered" macro-and-multi dose advanced psilocybin trial on 160 patients. The trial's primary indication (severe depression within PTSD) is...